Chronic administration of the nitroxyl donor 1-nitrosocyclo hexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes mellitus in vivo

Circulation. Heart Failure
Nga CaoRebecca H Ritchie

Abstract

Nitroxyl (HNO), a redox congener of nitric oxide (NO·), is a novel regulator of cardiovascular function, combining concomitant positive inotropic, lusitropic, and vasodilator properties. Moreover, HNO exhibits myocardial antihypertrophic and superoxide-suppressing actions. Despite these favorable actions, the impact of chronic HNO administration has yet to be reported in the context of cardiomyopathy. Diabetic cardiomyopathy is characterized by early diastolic dysfunction and adverse left ventricular (LV) structural remodeling, with LV superoxide generation playing a major causal role. We tested the hypothesis that the HNO donor 1-nitrosocyclohexylacetate (1-NCA) limits cardiomyocyte hypertrophy and LV diastolic dysfunction in a mouse model of diabetes mellitus in vivo. Diabetes mellitus was induced in male FVB/N mice using streptozotocin. After 4 weeks, diabetic and nondiabetic mice were allocated to 1-NCA therapy (83 mg/kg per day IP) or vehicle and followed up for a further 4 weeks. Diabetes mellitus-induced LV diastolic dysfunction was evident on echocardiography-derived E and A wave velocities, E:A ratio, deceleration, and isovolumic relaxation times; LV systolic function was preserved. Increased LV cardiomyocyte size, hyp...Continue Reading

References

Jan 1, 1997·Free Radical Biology & Medicine·S PfeifferB Mayer
Apr 26, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·F FiordalisoJ Kajstura
Aug 23, 2001·Proceedings of the National Academy of Sciences of the United States of America·N PaolocciD A Kass
Sep 18, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Kin M ChoiMohammed A Matlib
Apr 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nazareno PaolocciDavid A Kass
May 14, 2003·Hypertension·Jennifer C IrvineBarbara K Kemp-Harper
Jan 13, 2006·European Journal of Clinical Investigation·K-C ChangY-Z Tseng
Jul 18, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Shouji MatsushimaHiroyuki Tsutsui
Jul 27, 2006·Journal of the American Chemical Society·Xin ShaS Bruce King
Feb 21, 2007·Hypertension·Jennifer C IrvineBarbara K Kemp-Harper
Mar 3, 2007·The Journal of Physiology·Tieying DaiWei Dong Gao
Jun 26, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroyuki TsutsuiKenji Sunagawa
Jul 2, 2008·Free Radical Biology & Medicine·Jia YingRichard A Cohen
Aug 30, 2008·The American Journal of Medicine·Ashish AnejaMichael E Farkouh
Oct 7, 2008·Trends in Pharmacological Sciences·Jennifer C IrvineBarbara K Kemp-Harper
Mar 7, 2009·Circulation Research·Steve LancelWilson S Colucci
Sep 3, 2009·Pharmacology & Therapeutics·Rebecca H RitchieBarbara K Kemp-Harper
Nov 10, 2009·Diabetes Research and Clinical Practice·J E ShawP Z Zimmet
Dec 29, 2009·Frontiers in Bioscience (Elite Edition)·Mark J KohrMark T Ziolo
Aug 3, 2010·Antioxidants & Redox Signaling·Michelle L BullenBarbara K Kemp-Harper
Oct 16, 2010·Biochemical and Biophysical Research Communications·Ali El-ArmoucheSonia Donzelli
Jan 18, 2011·Antioxidants & Redox Signaling·Wilmarie Flores-SantanaDavid A Wink
Jan 18, 2011·Antioxidants & Redox Signaling·Carlo G TocchettiNazareno Paolocci
Jun 5, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Jennifer C IrvineRebecca H Ritchie
Aug 8, 2013·Antioxidants & Redox Signaling·Vidhya SivakumaranNazareno Paolocci
Oct 11, 2013·Circulation. Heart Failure·Hani N SabbahDavid A Kass
Jan 28, 2014·Pharmacology & Therapeutics·Karina HuynhRebecca H Ritchie

❮ Previous
Next ❯

Citations

Dec 23, 2006·Progress in Cardiovascular Diseases·Thomas H Marwick, Chiew Y Wong
Jul 2, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nicola KahlbergChen Huei Leo
Nov 5, 2019·Antioxidants & Redox Signaling·Cheng Xue QinRebecca Helen Ritchie
Mar 7, 2020·American Journal of Physiology. Heart and Circulatory Physiology·Darnel PrakosoRebecca Helen Ritchie
May 22, 2020·Circulation Research·Rebecca H Ritchie, E Dale Abel
May 10, 2019·Heart Failure Reviews·Yanqing GuoJian An
Jun 9, 2020·Frontiers in Pharmacology·Anida VelagicBarbara K Kemp-Harper
Jan 16, 2016·Oxidative Medicine and Cellular Longevity·Mai E Shoman, Omar M Aly
Aug 5, 2017·Frontiers in Endocrinology·Raffaele AltaraGeorge W Booz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.